Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/533198 |
| _version_ | 1827761663937347584 |
|---|---|
| author | Anke Kröcher Gunnar Folprecht Robert Winzer Mildred Sergon Martin Bornhäuser Jörg Kotzerke Claudia Brogsitter |
| author_facet | Anke Kröcher Gunnar Folprecht Robert Winzer Mildred Sergon Martin Bornhäuser Jörg Kotzerke Claudia Brogsitter |
| author_sort | Anke Kröcher |
| collection | DOAJ |
| description | Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography revealed a huge pelvic tumor without metastases. Initially, the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by 177Lu-DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 [225Ac]-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 months indicating that a combination therapy with an alpha emitter and olaparib demands further investigations in clinical trials. |
| first_indexed | 2024-03-11T10:16:10Z |
| format | Article |
| id | doaj.art-d3db1d0ff933404bb1783e2a6bcbe22c |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-03-11T10:16:10Z |
| publishDate | 2023-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-d3db1d0ff933404bb1783e2a6bcbe22c2023-11-16T07:58:20ZengKarger PublishersCase Reports in Oncology1662-65752023-10-011611166117110.1159/000533198533198Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA MutationAnke Kröcher0Gunnar Folprecht1Robert Winzer2Mildred Sergon3Martin Bornhäuser4Jörg Kotzerke5Claudia Brogsitter6Medical Department I, National Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyMedical Department I, National Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyDepartment of Pathology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyMedical Department I, National Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyBased on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography revealed a huge pelvic tumor without metastases. Initially, the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by 177Lu-DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 [225Ac]-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 months indicating that a combination therapy with an alpha emitter and olaparib demands further investigations in clinical trials.https://beta.karger.com/Article/FullText/533198brca mutationolaparibtargeted alpha-particle therapyneuroendocrine tumorpeptide receptor radionuclide therapy |
| spellingShingle | Anke Kröcher Gunnar Folprecht Robert Winzer Mildred Sergon Martin Bornhäuser Jörg Kotzerke Claudia Brogsitter Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation Case Reports in Oncology brca mutation olaparib targeted alpha-particle therapy neuroendocrine tumor peptide receptor radionuclide therapy |
| title | Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation |
| title_full | Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation |
| title_fullStr | Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation |
| title_full_unstemmed | Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation |
| title_short | Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation |
| title_sort | successful combination of olaparib and 225ac dotatate in a patient with neuroendocrine tumor g3 and brca mutation |
| topic | brca mutation olaparib targeted alpha-particle therapy neuroendocrine tumor peptide receptor radionuclide therapy |
| url | https://beta.karger.com/Article/FullText/533198 |
| work_keys_str_mv | AT ankekrocher successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation AT gunnarfolprecht successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation AT robertwinzer successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation AT mildredsergon successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation AT martinbornhauser successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation AT jorgkotzerke successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation AT claudiabrogsitter successfulcombinationofolapariband225acdotatateinapatientwithneuroendocrinetumorg3andbrcamutation |